A published review on the broadening applications of ISH in drug research and development

In situ hybridization (ISH) is being increasingly used in drug research and development for molecular experimental and toxicological pathology. While immunohistochemistry (IHC) has historically been the heavily favored method for the detection of proteins and other antigens, several factors appear to be diminishing its prominence. As observed in this 2023 paper, “Review of In Situ Hybridization Techniques for Drug Research and Development,” published in Toxicologic Pathology, these factors include:

• A lack of specific antibodies against a target of interest in humans or model species
• Novel or rare targets
• The development of nucleic acid-based therapeutics
• Easier accessibility of improved, ready-to-use ISH technologies

Because these reasons appear to be driving the rising adoption of ISH in drug research and development, the paper sought to review the techniques and current approaches and applications in the field. StageBio Director of Digital and Quantitative Pathology Thomas Lemarchand was a co-author of the paper, alongside his fellow members of the Pathology 2.0 Molecular Pathology Special Interest Group from the European Society of Toxicologic Pathology.

Takeaways found within the paper include observations of the fast-paced advancement of ISH in terms of probes and detection methods as well as visualization techniques.

Access “Review of In Situ Hybridization Techniques for Drug Research and Development” to learn the specifics of these advances in ISH and how they contribute to its increased adoption in drug research and development.

About StageBio

StageBio is a leading provider of GLP-compliant necropsy, histology, pathology, and specimen archiving and biorepository services for the biopharmaceutical, medical device, academic, and contract research industries. The company operates four GLP laboratories as well as three GLP specimen archiving facilities in the U.S., along with one GLP laboratory in Europe. StageBio will continue to make investments in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 30+ board-certified veterinary pathologists and more than 100 laboratory technicians on staff supporting our unified commitment to quality, scientific integrity, and client satisfaction. Learn more at  stagebio.com.